Search Results
Why Monthly Giving Matters
Giving regularly over time = giving patients and survivors the chance for more time.
Monthly giving really deserves more credit—credit as a predictable, impactful funding force for our lifesaving and life-changing work. For The Leukemia & Lymphoma Society (LLS), the reliability of a regular gift helps to sustain cutting-edge research and to provide the free resources and support blood cancer patients and survivors need to live longer, better lives.
It’s about ongoing generosity. It’s about creating a lasting impact.
And...
Contest Winner Turns Passion into Purpose
More than 3,000 votes are in, and The Leukemia & Lymphoma Society has officially announced the winner for the 2017 Light The Night T-shirt contest. Congratulations to 49-year-old Greg Cunningham of Raleigh, North Carolina!
Meet the Researcher: Omar Abdel-Wahab, MD
This is part of a periodic series of Q&A’s with LLS-funded researchers. Dr. Abdel-Wahab of Memorial Sloan Kettering Cancer Center focuses on an area of research called epigenetics – chemical modifications that regulate (switch on and off) gene activity. He is studying how these processes drive the development of acute myeloid leukemia and other blood cancers. He currently holds a Career Development Program grant from LLS, a program that supports scientists earlier in their careers.
Q. What is the focus of your research and its primary goal?
4 Things Cancer Patients Need to Know about the Coronavirus
The Leukemia & Lymphoma Society is closely monitoring the coronavirus (COVID-19) outbreak that originated in China and is spreading to other countries around the globe. As a health organization, one of our highest priorities is the well-being of the patients we serve – especially as many blood cancer patients are immunocompromised.
Key bill gains major traction in Congress, bringing children with cancer one step closer to faster care
The House Energy and Commerce Committee unanimously passed the Accelerating Kids' Access to Care Act. It's a key step toward the bill becoming law and ensuring kids can get cancer care without delay.State borders shouldn’t be barriers to treatment for children with cancer or other complex illnesses. Yet all too often, they cause challenges—or even treatment delays—for children and their families who rely on Medicaid or CHIP for their health insurance.
Remembering Robbie
On Friday, October 20, 1944, Robert “Robbie” Roesler de Villiers was only 16 years old when he died from leukemia. Robbie’s parents, Rudolph and Antoinette, were stricken with grief and frustrated by the lack of effective treatments for what was then considered a hopeless disease. In his memory, the family started a foundation in 1949.
A Special Surprise for Pediatric Cancer Patient Counting Down the Days until Treatment Ends
"A Style for Every Smile” Campaign is Brightening the Faces of Pediatric Cancer Patients like 4-Year-Old Sasha Nationwide
At the tender age of four, Sasha has endured more than most of us will in a lifetime. In October 2017, at just two years old, she was diagnosed with acute lymphoblastic leukemia, a diagnosis no parent wants to hear.
"It sounds so stereotypical, but I just didn't believe it. I was completely in denial,” says Sasha’s mom, Randi.
How to Save Lives through Virtual Fundraising Events
The adage, “We are all fighting the same storm, but we are not fighting it from the same boat,” is more relevant amidst today’s global pandemic than ever before. This resonates particularly true for cancer patients, who are at increased risk of getting sicker if they contract COVID-19.
Why We Love Nurses (And You Should Too!)
It makes sense that at diagnosis and throughout treatment, someone diagnosed with a blood cancer will look around them for answers or support.
“People Just Didn’t Get It”: Treating Young Adults with Cancer
Think of spring break: warm sunny skies, a refreshing drink, and hopefully, a feeling of freedom.
#ASH18: The Beat Goes On
On Sunday, I reported on a press briefing at the 60th ASH Annual Meeting where the preliminary findings of our Beat AML Master Clinical Trial were unveiled. This innovative collaborative study is designed to bring the hope of precision medicine to patients with acute myeloid leukemia (AML). (Read about our Friday ASH satellite symposium on immunotherapy here).